<p>Tiff Advisory Services LLC 在最近向证券交易委员会（SEC）提交的 13F 表格中披露，其在 The Oncology Institute, Inc.（NASDAQ:TOI - 免费报告）的持股在第四季度减少了 77.2%。该基金在此期间出售了 661,059 股后，持有该公司 195,569 股股票。Oncology Institute 占 Tiff Advisory Services LLC 投资组合的 0.1%，是其第 19 大持仓。截至其最近的 SEC 报告，Tiff Advisory Services LLC 持有的 Oncology Institute 价值约为 696,000 美元，约占 0.20%。</p>
<p>获取 <strong>Oncology Institute</strong> 警报：</p>
<p>其他几家机构投资者最近也调整了对该公司的持股。Larson Financial Group LLC 在第四季度将其在 Oncology Institute 的持仓增加了 19.7%。Larson Financial Group LLC 目前持有 31,468 股该公司股票，价值 112,000 美元，此前在上个季度又购买了 5,181 股。HighTower Advisors LLC 在第四季度将其在 Oncology Institute 的持仓增加了 5.5%。HighTower Advisors LLC 目前持有 85,851 股该公司股票，价值 306,000 美元，此前在上个季度又购买了 4,489 股。Pekin Hardy Strauss Inc. 在第四季度购买了 Oncology Institute 的新股份，价值 36,000 美元。R Squared Ltd 在第四季度购买了 Oncology Institute 的新股份，价值 41,000 美元。最后，Kingswood Wealth Advisors LLC 在第四季度将其在 Oncology Institute 的持仓增加了 27.2%。Kingswood Wealth Advisors LLC 目前持有 98,700 股该公司股票，价值 351,000 美元，此前在上个季度又购买了 21,100 股。36.86% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Oncology Institute 股票表现</h2>
<p>NASDAQ:TOI 的股票在周五开盘价为 4.59 美元。该公司的市值为 4.5368 亿美元，市盈率为 -12.41，贝塔值为 0.33。该股票的 50 日简单移动平均线为 3.50 美元，200 日简单移动平均线为 3.33 美元。The Oncology Institute, Inc. 的 52 周低点为 2.02 美元，52 周高点为 4.88 美元。</p>
<p>Oncology Institute（NASDAQ:TOI - 获取免费报告）最后一次公布财报是在 5 月 7 日星期四。该公司报告季度每股收益（EPS）为 -0.02，超出市场共识预期的 -0.07，超出幅度为 0.05 美元。该公司在本季度的收入为 1.4744 亿美元，而分析师预期为 1.4210 亿美元。整体来看，股票分析师预测 The Oncology Institute, Inc. 在当前财年将发布 -0.2 的每股收益。</p>
<h2>内部活动</h2>
<p>在相关消息中，主要股东 Jorey Chernett 于 3 月 13 日星期五收购了 263,000 股该公司的股票。该股票的购买均价为每股 2.92 美元，总价值为 767,960.00 美元。完成购买后，该内部人士直接持有 10,115,944 股该公司的股票，价值 29,538,556.48 美元。这代表其持股增加了 2.67%。该购买在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。此外，董事 Mohit Kaushal 于 4 月 14 日星期二出售了 57,286 股该公司的股票。该股票的出售均价为 3.50 美元，总价值为 200,501.00 美元。完成交易后，该董事直接持有 211,016 股该公司的股票，价值 738,556 美元。此交易代表其持仓减少了 21.35%。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士在过去九十天内购买了价值 2,038,896 美元的 637,485 股公司股票。公司内部人士持有该公司 8.50% 的股份。</p>
<h2>分析师评级变动</h2>
<p>几位研究分析师对 TOI 股票发布了报告。BTIG Research 在 3 月 9 日星期一的研究报告中重申了 “买入” 评级，并对 Oncology Institute 的股票设定了 7.00 美元的目标价。Weiss Ratings 在 4 月 20 日星期一的研究报告中重申了对 Oncology Institute 股票的 “卖出（d-）” 评级。B. Riley Financial 将 Oncology Institute 的目标价从 6.00 美元上调至 8.00 美元，并在 3 月 13 日星期五的研究报告中给予该股票 “买入” 评级。最后，Needham &amp; Company LLC 在 3 月 9 日星期一的研究报告中重申了 “买入” 评级，并对 Oncology Institute 的股票设定了 5.00 美元的目标价。四位股票研究分析师对该股票给予了 “买入” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，Oncology Institute 当前的平均评级为 “适度买入”，平均目标价为 7.00 美元。</p>
<p><strong>获取我们关于 Oncology Institute 的最新报告</strong></p>
<h2>Oncology Institute 简介</h2>
<p>（免费报告）</p>
<p>The Oncology Institute, Inc. 是一家肿瘤学公司，在美国提供各种医学肿瘤学服务。该公司通过三个部门运营：药房、患者服务和临床试验及其他。它提供医生服务、内部输液和药房、临床试验、放射治疗、门诊血液产品输血和患者支持服务，以及教育研讨会、支持小组和咨询服务。该公司还提供管理临床试验、姑息治疗项目、干细胞移植服务以及与非社区基础的学术和三级护理设置相关的其他护理交付模式；并为一系列制药和医疗设备公司进行临床试验。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票，而非肿瘤研究所</li>
<li>Workday 验证了 AI 飞轮：股价复苏开始</li>
<li>HubSpot 在 2019 年的水平是一个机会——而不是警告</li>
<li>Decker 的双重超预期是看涨信号——还是仅仅是 HOKA 的把戏？</li>
<li>Kiniksa Pharmaceuticals 在 100% 的反弹后仍有上涨空间</li>
</ul>
<p><strong>想看看其他对肿瘤研究所持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 The Oncology Institute, Inc. (NASDAQ:TOI - 免费报告) 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在肿瘤研究所吗？</h2>
<p>在你考虑肿瘤研究所之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而肿瘤研究所并不在名单上。</p>
<p>虽然肿瘤研究所目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

医药突破 ETF - ALPS

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

<p>Tiff Advisory Services LLC 在第四季度减少了对 The Oncology Institute, Inc. (NASDAQ:TOI) 的持股比例，降幅为 77.2%，目前持有 195,569 股。其他机构投资者也调整了他们的持仓。该股票开盘价为 4.59 美元，市值为 4.5368 亿美元。The Oncology Institute 报告每股收益为（0.02）美元，超出预期。分析师的评级各不相同，目标价格范围在 5.00 美元到 8.00 美元之间</p>

<p>Tiff Advisory Services LLC cut its holdings in shares of The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) by 77.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 195,569 shares of the company's stock after selling 661,059 shares during the period. Oncology Institute makes up 0.1% of Tiff Advisory Services LLC's portfolio, making the stock its 19th biggest position. Tiff Advisory Services LLC owned about 0.20% of Oncology Institute worth $696,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Tiff Advisory Services LLC 在最近向证券交易委员会（SEC）提交的 13F 表格中披露，其在 The Oncology Institute, Inc.（NASDAQ:TOI - 免费报告）的持股在第四季度减少了 77.2%。该基金在此期间出售了 661,059 股后，持有该公司 195,569 股股票。Oncology Institute 占 Tiff Advisory Services LLC 投资组合的 0.1%，是其第 19 大持仓。截至其最近的 SEC 报告，Tiff Advisory Services LLC 持有的 Oncology Institute 价值约为 696,000 美元，约占 0.20%。</p>
</div><p>Get <strong>Oncology Institute</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Oncology Institute</strong> 警报：</p>
</div><p>Several other institutional investors also recently modified their holdings of the business. Larson Financial Group LLC boosted its position in shares of Oncology Institute by 19.7% during the fourth quarter. Larson Financial Group LLC now owns 31,468 shares of the company's stock valued at $112,000 after buying an additional 5,181 shares during the last quarter. HighTower Advisors LLC boosted its position in shares of Oncology Institute by 5.5% during the fourth quarter. HighTower Advisors LLC now owns 85,851 shares of the company's stock valued at $306,000 after buying an additional 4,489 shares during the last quarter. Pekin Hardy Strauss Inc. purchased a new stake in shares of Oncology Institute during the fourth quarter valued at $36,000. R Squared Ltd purchased a new stake in shares of Oncology Institute during the fourth quarter valued at $41,000. Finally, Kingswood Wealth Advisors LLC boosted its position in shares of Oncology Institute by 27.2% during the fourth quarter. Kingswood Wealth Advisors LLC now owns 98,700 shares of the company's stock valued at $351,000 after buying an additional 21,100 shares during the last quarter. 36.86% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者最近也调整了对该公司的持股。Larson Financial Group LLC 在第四季度将其在 Oncology Institute 的持仓增加了 19.7%。Larson Financial Group LLC 目前持有 31,468 股该公司股票，价值 112,000 美元，此前在上个季度又购买了 5,181 股。HighTower Advisors LLC 在第四季度将其在 Oncology Institute 的持仓增加了 5.5%。HighTower Advisors LLC 目前持有 85,851 股该公司股票，价值 306,000 美元，此前在上个季度又购买了 4,489 股。Pekin Hardy Strauss Inc. 在第四季度购买了 Oncology Institute 的新股份，价值 36,000 美元。R Squared Ltd 在第四季度购买了 Oncology Institute 的新股份，价值 41,000 美元。最后，Kingswood Wealth Advisors LLC 在第四季度将其在 Oncology Institute 的持仓增加了 27.2%。Kingswood Wealth Advisors LLC 目前持有 98,700 股该公司股票，价值 351,000 美元，此前在上个季度又购买了 21,100 股。36.86% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Oncology Institute Stock Performance</h2>
<div class="lb-trans"><h2>Oncology Institute 股票表现</h2>
</div><p>Shares of NASDAQ:TOI opened at $4.59 on Friday. The stock has a market capitalization of $453.68 million, a price-to-earnings ratio of -12.41 and a beta of 0.33. The stock's 50-day simple moving average is $3.50 and its two-hundred day simple moving average is $3.33. The Oncology Institute, Inc. has a 52-week low of $2.02 and a 52-week high of $4.88.</p>
<div class="lb-trans"><p>NASDAQ:TOI 的股票在周五开盘价为 4.59 美元。该公司的市值为 4.5368 亿美元，市盈率为 -12.41，贝塔值为 0.33。该股票的 50 日简单移动平均线为 3.50 美元，200 日简单移动平均线为 3.33 美元。The Oncology Institute, Inc. 的 52 周低点为 2.02 美元，52 周高点为 4.88 美元。</p>
</div><p>Oncology Institute (NASDAQ:TOI - Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.05. The firm had revenue of $147.44 million during the quarter, compared to analysts' expectations of $142.10 million. As a group, equities analysts forecast that The Oncology Institute, Inc. will post -0.2 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Oncology Institute（NASDAQ:TOI - 获取免费报告）最后一次公布财报是在 5 月 7 日星期四。该公司报告季度每股收益（EPS）为 -0.02，超出市场共识预期的 -0.07，超出幅度为 0.05 美元。该公司在本季度的收入为 1.4744 亿美元，而分析师预期为 1.4210 亿美元。整体来看，股票分析师预测 The Oncology Institute, Inc. 在当前财年将发布 -0.2 的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In related news, major shareholder Jorey Chernett acquired 263,000 shares of the firm's stock in a transaction dated Friday, March 13th. The shares were purchased at an average price of $2.92 per share, with a total value of $767,960.00. Following the completion of the purchase, the insider directly owned 10,115,944 shares of the company's stock, valued at $29,538,556.48. This represents a 2.67% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, Director Mohit Kaushal sold 57,286 shares of the firm's stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $3.50, for a total value of $200,501.00. Following the completion of the transaction, the director directly owned 211,016 shares in the company, valued at $738,556. This trade represents a 21.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders bought 637,485 shares of company stock worth $2,038,896 in the last ninety days. Corporate insiders own 8.50% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，主要股东 Jorey Chernett 于 3 月 13 日星期五收购了 263,000 股该公司的股票。该股票的购买均价为每股 2.92 美元，总价值为 767,960.00 美元。完成购买后，该内部人士直接持有 10,115,944 股该公司的股票，价值 29,538,556.48 美元。这代表其持股增加了 2.67%。该购买在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。此外，董事 Mohit Kaushal 于 4 月 14 日星期二出售了 57,286 股该公司的股票。该股票的出售均价为 3.50 美元，总价值为 200,501.00 美元。完成交易后，该董事直接持有 211,016 股该公司的股票，价值 738,556 美元。此交易代表其持仓减少了 21.35%。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士在过去九十天内购买了价值 2,038,896 美元的 637,485 股公司股票。公司内部人士持有该公司 8.50% 的股份。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several research analysts have issued reports on TOI shares. BTIG Research reissued a &#34;buy&#34; rating and issued a $7.00 target price on shares of Oncology Institute in a research report on Monday, March 9th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Oncology Institute in a research report on Monday, April 20th. B. Riley Financial raised their target price on Oncology Institute from $6.00 to $8.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, March 13th. Finally, Needham &amp; Company LLC reissued a &#34;buy&#34; rating and issued a $5.00 target price on shares of Oncology Institute in a research report on Monday, March 9th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Oncology Institute currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $7.00.</p>
<div class="lb-trans"><p>几位研究分析师对 TOI 股票发布了报告。BTIG Research 在 3 月 9 日星期一的研究报告中重申了 “买入” 评级，并对 Oncology Institute 的股票设定了 7.00 美元的目标价。Weiss Ratings 在 4 月 20 日星期一的研究报告中重申了对 Oncology Institute 股票的 “卖出（d-）” 评级。B. Riley Financial 将 Oncology Institute 的目标价从 6.00 美元上调至 8.00 美元，并在 3 月 13 日星期五的研究报告中给予该股票 “买入” 评级。最后，Needham &amp; Company LLC 在 3 月 9 日星期一的研究报告中重申了 “买入” 评级，并对 Oncology Institute 的股票设定了 5.00 美元的目标价。四位股票研究分析师对该股票给予了 “买入” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，Oncology Institute 当前的平均评级为 “适度买入”，平均目标价为 7.00 美元。</p>
</div><p><strong>Get Our Latest Report on Oncology Institute</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Oncology Institute 的最新报告</strong></p>
</div><h2>Oncology Institute Profile</h2>
<div class="lb-trans"><h2>Oncology Institute 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials &amp; Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.</p>
<div class="lb-trans"><p>The Oncology Institute, Inc. 是一家肿瘤学公司，在美国提供各种医学肿瘤学服务。该公司通过三个部门运营：药房、患者服务和临床试验及其他。它提供医生服务、内部输液和药房、临床试验、放射治疗、门诊血液产品输血和患者支持服务，以及教育研讨会、支持小组和咨询服务。该公司还提供管理临床试验、姑息治疗项目、干细胞移植服务以及与非社区基础的学术和三级护理设置相关的其他护理交付模式；并为一系列制药和医疗设备公司进行临床试验。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than Oncology Institute</li>
<li>Workday Validates AI Flywheel: Stock Price Recovery Begins</li>
<li>HubSpot at 2019 Levels Is an Opportunity—Not a Warning</li>
<li>Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?</li>
<li>Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非肿瘤研究所</li>
<li>Workday 验证了 AI 飞轮：股价复苏开始</li>
<li>HubSpot 在 2019 年的水平是一个机会——而不是警告</li>
<li>Decker 的双重超预期是看涨信号——还是仅仅是 HOKA 的把戏？</li>
<li>Kiniksa Pharmaceuticals 在 100% 的反弹后仍有上涨空间</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TOI?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Oncology Institute, Inc. (NASDAQ:TOI - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对肿瘤研究所持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 The Oncology Institute, Inc. (NASDAQ:TOI - 免费报告) 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TOI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Oncology Institute Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在肿瘤研究所吗？</h2>
</div><p>Before you consider Oncology Institute, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑肿瘤研究所之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncology Institute wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而肿瘤研究所并不在名单上。</p>
</div><p>While Oncology Institute currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然肿瘤研究所目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Tiff Advisory Services LLC Reduces Position in The Oncology Institute, Inc. $TOI

Market Beat

Oncology Institute

Oncology Institute - CW22

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存托优先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

Tiff Advisory Services LLC 减少了在 The Oncology Institute, Inc. 的头寸 $TOI